Replimune to face AdCom panel as lead drug accepted for FDA review
Seeking Alpha ·
Replimune ( REPL ) shares slipped in the premarket on Friday after the company announced that the FDA will convene an advisory committee to review its lead drug, RP1, following the regulator's acceptance of its resubmitted marketing application. The Massachusetts-based biotech’s Biologics
DYAX Investor Sentiment
Bullish (Long) 58% · Bearish (Short) 42%
486 participants
Related News
- Barnes & Noble Education establishes a multi-year runway for growth -- Needham
- Safran in talks to buy French sea drone maker Exail Technologies
- Goldman Sachs turns bullish on regional casino players PENN and Red Rock Resorts
- Mag 7 gets dethroned inside the Nasdaq
- Update: Tech Stocks Drag Down Equity Index Futures Pre-Bell Amid AI, Gulf Worries
- The Duolingo Rally Is Finally Starting